References

1. Van Schoor GM, Crooks L, Busner J, Byrom B. Underrepresented Populations in Clinical Trials: Considerations, Diversity, Accessibility, and Patient Centricity. Signant Health White Paper; 2024.
2. Sharma A, Palaniappan L. Improving diversity in medical research. Nat Rev Dis Primers. 2021;7(11).
3. Carter-Edwards L, Hidalgo B, Lewis-Hall F, Nguyen T, Rutter J. Diversity, equity, inclusion, and access are necessary for clinical trial site readiness. J Clin Transl Sci. 2023;7(1):e268.
4. Oyer RA, Hurley P, Boehmer L, et al. Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J Clin Oncol. 2022;40(19):2163-2171. doi:10.1200/JCO.22.00754
5. Reopell L, Nolan TS, Gray DM 2nd, et al. Community engagement and clinical trial diversity: navigating barriers and co-designing solutions-a report from the "Health Equity through Diversity" seminar series. PLoS One. 2023;18(2):e0281940. doi:10.1371/journal.pone.0281940
6. Huang B, De Vore D, Chirinos C, et al. Strategies for recruitment and retention of underrepresented populations with chronic obstructive pulmonary disease for a clinical trial. BMC Med Res Methodol. 2019;19:1-10.
7. Recruiting Special Patient Populations. Appl Clin Trials. 2006.
8. Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148-172.
9. McPhillips MV, Petrovsky DV, Brewster GS, et al. Recruiting persons with dementia and caregivers in a clinical trial: dyads perceptions. West J Nurs Res. 2022;44(6):557-566.
10. US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Draft Guidance for Industry [withdrawn]. FDA; 2024.
11. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14(1):263-292.
12. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):1-22.
13. Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022;328(1):57-68.

14. Lebensburger JD, Sidonio RF, DeBaun MR, et al. Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer. 2013;60(8):1333-1337.
15. Badawy SM. Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework. Hematology Am Soc Hematol Educ Program. 2021;2021(1):196-205.
16. Clark III D, Woods J, Patki D, et al. Digital informed consent in rural and low-income population. JAMA Cardiol. 2020;5(7):845-847.
17. Almeida-Magana R, Maroof H, Grierson J, et al. E-Consent – a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. Trials. 2022;23:388.
18. Weiddler EH, Naumann T, Andersson T, et al. The role of machine learning in clinical research: transforming the future of evidence generation. Trials. 2021;22:537.
19. MacIntyre MR, Cockerill RG, Mirza OF, Appel JM. Ethical considerations for the use of artificial intelligence in medical decision-making capacity assessments. Psychiatry Res. 2023;328:115466.
20. Chereji R. Translating "medicalese": the case of informed consent forms. Med Writ. 2024;33(1):44-47.
21. Bickmore T, Utami D, Zhou S, et al. Automated explanation of research informed consent by virtual agents. Intelligent Virtual Agents. 2015;9238:260-269.
22. Xiao Z, Li TW, Karahalios K, Sundaram H. Inform the uninformed: improving online informed consent reading with an AI-powered chatbot. CHI '23: Proceedings of the 2023 CHI Conference on Human Factors in Computing Systems. 2023;112:1-17.